Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

LinkedIn Corp (LNKD), Regeneron Pharmaceuticals Inc (REGN): 5 Stocks You Can Sell Right Now

Page 1 of 2

In April of last year I decided that the boundaries of financial metrics no longer mattered to me, and I embarked on creating my own unique index, dubbed the TMFULOI, to examine and help me determine what the most overvalued companies in the market were.

Far from an exact science, the TMFULOI takes into account a company’s book value, price-to-sales, and price-to-cash flow ratio, allowing me to compare companies based on set parameters, which you can read more about here. Through the first two rounds of utilizing my index I was able to handily beat the S&P 500, my benchmark index, with the cumulative five stocks underperforming the S&P 500.

LinkedIn Corp (NYSE:LNKD)

In my most recent instance using the TMFULOI, I added a growth discount parameter suggested by my Foolish colleague Rick Munarriz, who correctly pointed out that the initial TMFULOI valuation model I was using failed to account for, and even punished, rapidly growing companies. Having completed a third round using my newly adjusted TMFULOI value, I’m happy to say I have yet again surpassed the S&P 500 and am now a perfect three-for-three, despite LinkedIn Corp (NYSE:LNKD) being a thorn in my side once again!

Company Performance Since Feb. 19, 2013 Performance Relative to S&P 500
ARM Holdings plc (ADR) (NASDAQ:ARMH) (16.4%) (21.9%)
LinkedIn Corp (NYSE:LNKD) 13.9% 8.4%
Aspen Technology, Inc. (NASDAQ:AZPN) (4.4%) (9.9%)
SolarWinds Inc (NYSE:SWI) (27.6%) (33.1%)
Mercadolibre Inc (NASDAQ:MELI) 27.9% 22.4%

Source: Yahoo! Finance.

All told, this grouping of the five most overvalued companies according to my valuation metric underperformed the S&P 500 by an average of 6.8%!

Now, it’s time for a new round of the market’s most overvalued companies. It’s been said that once is luck but three is a trend, so let’s see if I can make this four in a row for my adjusted valuation metric!

Company Price/ Book Price/ Sales Price/ Cash Flow TMFULOI Forward Sales Growth % Adjusted TMFULOI
Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
16 16.8 270.3 303.1 27.1% 11.18
Qihoo 360 Technology Co Ltd (NYSE:QIHU) 11.5 15.7 90.9 118.1 40.7% 2.90
Yandex NV (NASDAQ:YNDX) 27.7 10 25 62.7 23.6% 2.66
LinkedIn Corp (NYSE:LNKD) 20.4 18.8 67.6 106.8 41% 2.60
Tripadvisor Inc (NASDAQ:TRIP) 10.9 10.8 34.6 56.3 22.3% 2.52
MercadoLibre 15.9 12.2 31.6 59.7 25% 2.39

Sources: Morningstar, Yahoo! Finance, Motley Fool CAPS Screener, author’s calculations.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Normally I exclude biotechnology companies from these rankings because they often skew the index, but Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been healthily profitable for some time now. Even though I made the company’s lead drug, Eylea (which treats wet age-related macular degeneration), my primary selection if I were to build a biotech dream team, the valuation here is getting out of hand according to my TMFULOI. The real concern would be Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s free cash flow, which is being directed, almost in its entirety, at additional research and development. With a growth rate of 27.1% in 2014, Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s forward P/E of 38 isn’t too horrific, but it’ll need Eylea sales to pretty much knock Wall Street off its feet in each and every quarter if it hopes to maintain this lofty valuation.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!